Class summary at a glance.

Every drug in the Somatostatin Analog class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $24.4Mcombined across class
Total Rx claims: 25K6K unique beneficiaries
Generic mfrs (active): 9across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Octreotide

Brand: BYNFEZIA Pen · 25K Part D claims (CY24) · 6K beneficiaries · First FDA approval: 1988-10-21

9 generic mfrs 1238 plans require PA

Low NADAC$2.64

→

Avg plan cost$906.67

Part D spend $24.4M 343× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Pasireotide

Brand: Signifor · — Part D claims (CY24) · First FDA approval: 2012-12-14

Brand-only (no generics) 969 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.